Skip to main content

Elicio Therapeutics, Inc.

ELTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001601485

No open-market purchases or sales by Elicio Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $15.3M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Elicio Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of ELTX: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders4147+6
Shares5.03M7.09M+2.06M (+41.0%)
Value$66.5M$69.3M+$2.77M (+4.2%)

New holders (14)

Institutions that held Elicio Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to ELTX in Q3 2021
InstitutionSharesValue% of portfolio
Russell Investments Group, Ltd.248,092$2.42M0.00%
Bank of New York Mellon Corp41,887$409.0K0.00%
Valeo Financial Advisors, LLC37,400$365.0K0.02%
Nuveen Asset Management, LLC32,142$338.0K0.00%
Steward Partners Investment Advisory, LLC15,558$152.0K0.00%
Price T Rowe Associates Inc12,695$124.0K0.00%
Manufacturers Life Insurance Company, The11,708$114.0K0.00%
Rhumbline Advisers10,947$107.0K0.00%
MetLife Investment Management9,809$95.8K0.00%
Metropolitan Life Insurance Co7,421$72.5K0.00%
Advisor Group Holdings, Inc.2,333$23.0K0.00%
US Bancorp105$1.00K0.00%
Signaturefd, LLC58$1.00K0.00%
Lindbrook Capital, LLC28$00.00%

Sold out (8)

Institutions that held Elicio Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of ELTX in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
HRT Financial LP59,857$779.0K
Jacobs Levy Equity Management, Inc57,146$744.0K
Millennium Management LLC48,059$626.0K
Alyeska Investment Group, L.P.32,239$420.0K
Citadel Advisors LLC23,864$311.0K
Ergoteles LLC23,917$311.0K
UBS Group AG217$3.00K
TCI Wealth Advisors, Inc.37$0